overview   |   leadership   |   scientific advisory board   |   investors

scientific advisory board

Also supporting the Company’s efforts is a Scientific Advisory Board featuring some of the most renowned scientific experts within the field of cancer metabolism and oncology.

Chair of the Scientific Advisory Board:
Craig B. Thompson, M.D., University of Pennsylvania and Abramson
Cancer Center

Paul S. Anderson, Ph.D., Retired executive of Bristol-Myers Squibb and Merck

Lewis C. Cantley, Ph.D., Beth Israel Deaconess Medical Center and Harvard Medical School

Chi Dang, M.D., Ph.D., The Johns Hopkins Family Professor in Oncology Research; Professor of Medicine, Cell Biology, Oncology and Pathology; Vice Dean for Research, School of Medicine

Ronald A. DePinho, M.D., Dana-Farber Cancer Institute and Harvard
Medical School

Tak W. Mak, Ph.D., University of Toronto and The Campbell Family Institute
for Breast Cancer Research

Pier Paolo Pandolfi, M.D., Ph.D., Beth Israel Deaconess Medical Center

Homer L. Pearce, Ph.D., Retired executive of Eli Lilly & Company

David M. Sabatini, M.D., Ph.D., Whitehead Institute and Massachusetts
Institute of Technology

Charles Sawyers, M.D., Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center

Bruce M. Spiegelman, Ph.D., Dana-Farber Cancer Institute and Harvard
Medical School

[ back to top ]